CLINICAL_TRIALS
trial_result
· 2025-01-08
Clinical Trial Update: Gene Therapy for X-linked Retinitis Pigmentosa (XLRP) - Retinitis Pigmentosa GTPase Regulator (RPGR) [Phase 1, Phase 2]
Summary
A phase 1/2 gene therapy trial targeting RPGR in X-linked Retinitis Pigmentosa has completed and posted results in January 2025.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: MeiraGTx UK II Ltd | Conditions: X-Linked Retinitis Pigmentosa | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2025-01-08